drugset / Trial / NCT05890534

Pycnogenol® in Post-COVID-19 Condition

NCT05890534 ↗

Phase 3 Completed 153 enrolled University of Zurich
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine the effect of Pycnogenol® versus placebo on patient-reported health status in people with post COVID-19 condition.

Timeline

Start
2023-06-07
Primary completion
2024-11-05
Completion
2025-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject MARITIME PINE Traditional medicine (herbal / TCM) 200 mg —

Indications